

## ASAM Moving Beyond Barriers of Treating Opioid Use Disorder Course

### References

- Huhn, AS, et al, Protracted renal clearance of fentanyl in person with opioid use disorder. *Drug and Alcohol Dependence*. 2020; 214: 1-4
- Jones, C. Comparison between buprenorphine provider availability and opioid deaths amount US counties. *J Subs Abuse*. 2018; 93: 12-25.
- Dunn, K. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. *Drug and Alc Depend*. 2011; 119: 1-9.
- Cicero, T. Understanding the use of diverted buprenorphine. *Drug and Alc Depend*. 2018; 193: 117-123.
- Williams, A. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. *AJP in Advance*. 2019; 1-8.
- Bentzley, B. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. *J Subs Abuse*. 2015; 5: 48-57.
- Comer, S. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. *Drug and Alc Depend*. 2014; 144: 1-11.
- Andrilla, C. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. *J of Rural Health*. 2019; 35: 108-112.
- Socias, M. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. *Addiction*. 2018; 1-9.
- Wakeman, S. Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA*. 2020; 1-12.
- Langleben, D. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. *Am J. Psychiatry*. 2008; 165: 390-394.
- Kaufman, M. Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. *Psych Research*. 1999; 90: 143-152.
- Sordo, L. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ*. 2017; 357: 1-14.
- Gronbladh, L. Mortality of heroin addiction: impact of methadone treatment. *Acta Psychiatr Scand*. 1990; 82: 223-227.
- Herring, A. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder. *Amer J of Emer Med*. 2019; 37(12): 2259-2262.
- Bohnert, A. Understanding links among opioid use, overdose, and suicide. *New Eng J Med*. 2019; 380: 71-79.

Pergolizzi, J. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. *J Pain Research*. 2019; 12: 3299-3317.

Weiss, R. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. *Arch Gen Psychiatry*. 2011; 68(12): 1238-1246.

Day, E. Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism? *Addiction*. 2017; 1-7.

Amato, L. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Data Sys Rev*. 2011.

Dugosh, K. A systematic review of the user of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. *J Addict Med*. 2016; 10: 93-103.

Carroll, K. The role of behavioral interventions in buprenorphine maintenance treatment: a review. *Am J Psychiatry*. 2017; 174: 738-747.

Saxon, A. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug and Alc Depend*. 2013; 128: 71-76.

Lofwall M. A review of buprenorphine diversion and misuse: the current evidence based and experiences from around the world. *JAM*. 2014; 8(5): 315-326.

Haffajee, R. Policy pathways to address provider workforce barriers to buprenorphine treatment. *Am J Prev Med*. 2018; 54(6): S230-242.

Clark, R. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. *Health Serv Research*. 2014; 49(6).

Burns, R. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. *Subs Abuse*. 2016; 37(1): 63-69.

Grogan, C. Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications. *Health Affairs*. 2016; 35(12).

US Department of Health and Human Services. Parity Policy and Implementation. 2018.

ASAM